吉利德科学(GILD)今日盘中股价大幅上涨5.05%，引起了市场的广泛关注。
消息面上，公司此前发布的2026年财务指引略低于市场预期，导致股价盘前承压。然而，华尔街多家投行发布报告，表达了对公司下一代艾滋病预防药物Yeztugo长期潜力的支持，认为其销售仍有上升空间，这为股价提供了强劲支撑。
此外，公司公布的2025年财报显示净利润同比激增近17倍，核心HIV业务增长稳健，同时董事会批准提高季度现金股息。加拿大皇家银行(RBC)等机构随后上调了公司目标价。多重积极因素共同作用下，推动股价在盘中逆转走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.